H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4.
Akebia Therapeutics Inc. (AKBA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Great Point Partners Jeffrey Jay And David Kroin | 4,973,840 | $9,549,773 | 5.06% | |
| 2. | Renaissance Technologies Jim Simons | 4,005,827 | $7,691,188 | +5% | 0.01% |
| 3. | Citadel Investment Group Ken Griffin | 3,646,909 | $7,002,066 | +164% | 0% |
| 4. | AIGH Investment Partners Orin Hirschman | 2,925,000 | $5,616,000 | 2.32% | |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 2,485,578 | $4,772,310 | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.43 | 5,800 | $19,894.00 | 29,731 | 2019-11-20 | Filing | |
| $3.52 | 15,000 | $52,800.00 | 28,700 | 2019-11-20 | Filing | |
| $3.58 | 27,000 | $96,660.00 | 37,000 | 2019-11-20 | Filing | |
| $3.44 | 50,000 | $172,000.00 | 887,732 | 2019-11-20 | Filing | |
| $3.41 | 50,000 | $170,500.00 | 63,700 | 2019-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.01 | 15,000 | $60,150.00 | 266,914 | 2025-06-09 | Filing | |
| $3.53 | 13,334 | $47,069.02 | 266,914 | 2025-06-04 | Filing | |
| $1.83 | 46,409 | $84,928.47 | 2,557,921 | 2025-03-03 | Filing | |
| $1.83 | 7,144 | $13,073.52 | 809,090 | 2025-03-03 | Filing | |
| $2.10 | 97,982 | $205,762.20 | 2,604,330 | 2025-02-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,332,163 | $29,437,752 | 0% | |
| 2. | 12,685,803 | $24,356,741 | 0% | |
| 3. | 350,413 | $20,496,484 | 0.01% | |
| 4. | 6,805,807 | $13,067,149 | 0% | |
| 5. | 5,030,740 | $9,661,509 | 0% |
News See All
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to Akebia's First Quarter 2025 Financial Results Call. At this time, all participants are in a listen-only mode.
12 Best Stocks to Invest in for a Stock Market Game
We all have heard the phrase ‘value isn’t always visible at first glance’ at least once in our lifetime and this isn’t something to overlook, particularly when you are playing the stock game.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2024 Earnings Call Transcript
Operator: Good day, and welcome to Akebia's Fourth Quarter 2024 Financial Results Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Akebia's Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08775, expectations were $-0.09.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Akebia Therapeutics' Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2023 Earnings Call Transcript
Operator: Good day and welcome to Akebia's Second Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Akebia's First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript
Operator: Good day ladies and gentlemen. Thank you for standing by and welcome to Akebia's Fourth Quarter 2022 Financial Results Conference Call.
Billionaire Hedge Funds
